AstraZeneca highlights continued progress of oncology pipeline at 2016 ASCO Annual Meeting

Click here to view online. Add this email to your safelist.

19 May 2016

AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive oncology pipeline at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA, on 3-7 June 2016.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.